Allied Market Research

2024

Allergic Rhinitis Market

Allergic Rhinitis Market Size, Share, Competitive Landscape and Trend Analysis Report by drug class, by route of administration and by form : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Allergic rhinitis is an allergic response to specific allergens. An allergen is an otherwise harmless substance that has the ability to cause an allergic reaction in conducive conditions. Pollen is the most common allergen in seasonal allergic rhinitis. Mold, animal dander, and dust are the other substances that can cause allergic rhinitis.

Increase in the prevalence of allergic rhinitis augments the market growth. Furthermore, rise in the awareness about allergic rhinitis and high usage of tobacco boost the allergic rhinitis market. However, patent expiries and competition from generic drugs along with growth in the preference for alternative & complementary therapy impedes the growth of the market.

The global allergic rhinitis market is segmented on the basis of drug class, route of administration, form, and geography. By drug class, this market is segmented into antihistamines, intranasal corticosteroids, and immunotherapies. By route of administration, this market is classified into oral, parenteral, and intranasal. Furthermore, on the basis of form, this market is categorised into solid and liquid. By geography, it has been analysed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as GlaxoSmithKline, Sanofi, ALK-Abell, Meda Pharmaceuticals, Merck & Co., Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and Alcon (Novartis AG) have been provided in this report.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate imminent investment pockets.
  • It offers a quantitative analysis to enable stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions has been provided to determine prevailing opportunities.
  • Key players have been profiled and their strategies thoroughly analyzed to understand the competitive outlook of the global market.
  • Extensive analysis by product elucidates the use of allergic rhinitis drugs in medical settings.

Allergic Rhinitis Market Report Highlights

Aspects Details
icon_5
By drug class
  • Antihistamines
  • Intranasal corticosteroids
  • Immunotherapies
icon_6
By route of administration
  • Oral
  • Parenteral
  • Intranasal
icon_7
By form
  • Solid
  • Liquid
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_9
Key Market Players

GlaxoSmithKline, ALK-Abell, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Sanofi, Merck & Co., Meda Pharmaceuticals, Alcon (Novartis AG)

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Allergic Rhinitis Market

Global Opportunity Analysis and Industry Forecast, 2023-2032